Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

Launched by MOHAMED NABIL ELKHOLY · Jul 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Dapagliflozin on heart recovery in patients who have experienced a specific type of heart attack known as an anterior STEMI. The trial will include 120 participants who will be divided into groups based on whether they have diabetes and if they will be taking Dapagliflozin alongside their regular heart treatment. The goal is to see how Dapagliflozin affects heart function and structure during the first three months after a heart attack.

To participate in this trial, individuals must have had symptoms of a heart attack within the last 48 hours and be able to provide consent. Some key exclusions include those with a history of previous heart attacks, certain heart conditions, or kidney problems. Participants can expect to undergo heart imaging tests shortly after their hospital admission and again three months later to monitor how well their heart is healing. Overall, the study aims to provide insights into whether Dapagliflozin can improve heart recovery for patients after a serious heart event.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • STEMI with time from symptom onset of \<48 hours duration.
• • Capable of giving signed informed consent.
• Exclusion Criteria:
• • Patients with a history of old myocardial infarction.
• • Patients with a history of previous coronary artery bypass surgery (CABG).
• • Hemodynamically unstable patients.
• • Patients with suboptimal echocardiographic images
• • Patients with any cardiac rhythm other than sinus rhythm.
• • Unsuccessful angiographic reperfusion (Thrombolysis In Myocardial Infarction \[TIMI\] flow grade \<2).
• • Patients with renal dysfunction. (GFR\<30mmol/L).
• • Patients who have recently undergone immunosuppressive therapy.
• • Patients with a history of recurrent urinary tract infections.
• • Patients who are known to be allergic to SGLT-2 inhibitors.
• • Chronic symptomatic heart failure within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization.
• • Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial.
• • Any other non cardiovascular diseases, such as active malignancy requiring treatment at the time of screening or with a life expectancy of fewer than two years based on the investigator´s clinical judgment.
• • Currently on treatment with a sodium-glucose co-transporter 2 inhibitor (SGLT2-inhibitors).